Piper Sandler analyst Matt O’Brien raised the firm’s price target on Avita Medical (RCEL) to $12 from $9 and keeps a Neutral rating on the shares after Q3 results. While there are several growth drivers looking to next year, Piper remains cautious on the near-term outlook and thus remain on the sidelines, it told investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.